### Learner Notification

**American College of Medical Toxicology**

**2023 ACMT Annual Scientific Meeting**

**March 31, 2023 – April 2, 2023  
San Diego, CA**

**Acknowledgement of Financial Commercial Support**

BTG - $12,500

**Acknowledgement of In-Kind Commercial Support**

No in-kind commercial support was received for this educational activity.

**Satisfactory Completion**

Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. OR You must attend the entire webinar as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

**Joint Accreditation Statement**

A picture containing drawing

Description automatically generatedIn support of improving patient care, this activity has been planned and implemented by Amedco LLC and American College of Medical Toxicology. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

**Physicians (ACCME) Credit Designation**

Amedco LLC designates this live activity for a maximum of 14.75 *AMA PRA Category 1 Credits*TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Nurses (ANCC) Credit Designation**

Amedco LLC designates this activity for a maximum of 14.75 ANCC contact hours.

**Pharmacists and Pharmacy Technicians (ACPE) Credit Designation**

Amedco LLC designates this activity for a maximum of 14.75 knowledge-based CPE contact hours.

Pharmacy Designation 1 - Activity ID: 202448599 / Internal ID: ACMT / UAN JA4008163-9999-23-082-L01-P / UAN JA4008163-9999-23-082-L01-T

Pharmacy Designation 8 - Activity ID: 202448601 // Internal ID: ACMT / UAN JA4008163-9999-23-083-L08-P / UAN JA4008163-9999-23-083-L08-T

Pharmacy Designation 9 - Activity ID: 202448605 / Internal ID: ACMT / UAN JA4008163-9999-23-084-L99-P / UAN JA4008163-9999-23-084-L99-T

Pharmacy Designation 4 - Activity ID: 202448609 / Internal ID: ACMT / UAN JA4008163-9999-23-085-L04-P / UAN JA4008163-9999-23-085-L04-T

Pharmacy Designation 7 - Activity ID: 202448614 / Internal ID: ACMT / UAN JA4008163-9999-23-086-L07-P / UAN JA4008163-9999-23-086-L07-T

**NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.**

###### Objectives - After Attending This Program You Should Be Able To

1. Strengthen professional relationships and networks that lead to better patient care.
2. Develop and refine a perspective on the broad range of medical toxicology knowledge, care and clinical practice.
3. Expand and integrate an understanding of the scientific and clinical tenets of medical toxicology research.

**Disclosure of Conflict of Interest**

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-­‐6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

|  |  |  |
| --- | --- | --- |
| **First Name** | **Last Name** | **Commercial Interest: Commercial Interest** |
| Jay | Adams | NA |
| Maryann | Amirshahi | NA |
| Gillian | Beauchamp | NA |
| Mary | Billington | NA |
| Adam | Blumenberg | Inspira technologies: Stock Shareholder |
| Katie | Boyle | Alnylam Pharmaceuticals: Employee |
| Nicklaus | Brandehoff | NA |
| Marielle | Brenner | NA |
| Jeff | Brent | NA |
| Diane | Calello | NA |
| Vincent | Calleo | NA |
| Dazhe | Cao | NA |
| Joe | Carpenter | NA |
| Stephanie | Carreiro | RAE Health: Research Grant Overall Principal Investigator |
| Shaun | Carstairs | NA |
| Alexis | Cates | NA |
| Peter | Chai | NA |
| Andrew | Chambers | NA |
| Betty Shuk Han | Chan | NA |
| Michael | Chary | NA |
| James | Chenoweth | NA |
| Neeraj | Chhabra | NA |
| Jon | Cole | NA |
| Ryan | Cole | NA |
| Nicholas | Connors | NA |
| Rachel | Culbreth | CAIRE, Inc.: Research Grant Site Principal Investigator,CAIRE, Inc.: Consultant |
| Arthur | Daigh | NA |
| Josh | Debord | NA |
| Frank | Dicker | NA |
| Christopher | Dion | NA |
| Ryan | Dixon | NA |
| Catherine | Dong | NA |
| Adrienne | Dunavin | NA |
| Leslie | Dye | NA |
| Paul | Ehlers | NA |
| Tharwat | El Zahran | NA |
| Rita | Farah | NA |
| Brenna | Farmer | NA |
| Ryan | Fuchs | NA |
| Henrik | Galust | NA |
| Anna | Gerald | NA |
| Lucinda | Gonzales | NA |
| Howard | Greller | NA |
| Riley | Hartmann | NA |
| Hannah | Hays | NA |
| Robert | Hendrickson | NA |
| Michelle | Hieger | NA |
| Ruby | Hoang | NA |
| Zane | Horowitz | NA |
| David | Jang | NA |
| David | Juurlink | NA |
| Louise | Kao | NA |
| Kenneth | Katz | NA |
| Katherine | Katzung | NA |
| Ziad | Kazzi | NA |
| Michael | Keenan | NA |
| Joe | Kennedy | NA |
| Andrew | King | NA |
| Jessica | Krueger | NA |
| Shana | Kusin | NA |
| JoAn | Laes | NA |
| Daniel | Lasoff | NA |
| Ophir | Lavon | NA |
| Eric | Lavonas | BTG Specialty Pharmaceuticals: Research Grant Site Principal Investigator |
| Alex | Lazar | NA |
| Jacob | Lebin | Purdue Pharma: Consultant |
| Vincent | Lee | NA |
| Lorenzo | Leggio | Editor-in-Chief, Alcohol and Alcoholism (Oxford Press and MCA, London, UK):Other Financial or Material Support,Routledge: Other |
| Michael | Levine | NA |
| Brian | Lewis | NA |
| David | Liss | NA |
| Annette | Lopez | NA |
| Gregory | Makar | NA |
| Alex | Manini | NA |
| Ryan | Marino | NA |
| Kevin | Maskell | NA |
| Dan | McCabe | NA |
| Christopher | Meaden | NA |
| Alison | Meyn | NA |
| Andrew | MONTE | NIH: Research Grant Site Principal Investigator |
| Elizabeth | Moore | NA |
| Babak | Mostafazadeh | NA |
| Mark | Mycyk | NA |
| Travis | Olives | NA |
| Renee | Petzel Gimbar | Xeris Pharmaceuticals : Research Grant Overall Principal Investigator |
| Todd | Phillips | NA |
| Andrew | Piner | NA |
| Anthony | Pizon | NA |
| J.J. | Rasimas | NA |
| Madeline | Renny | NA |
| Tony | Rianprakaisang | NA |
| Patricia | Rosen | NA |
| Anne-Michelle | Ruha | Ophirex: Consultant |
| Matthew | Salzman | NA |
| David | Schaffer | NA |
| Jonathan | Schimmel | Bioxcel Therapeutics: Consultant |
| Evan | Schwarz | NA |
| Daniel | Sessions | NA |
| Michael | Simpson | NA |
| Craig | Smollin | NA |
| Hannah | Spungen | NA |
| Meghan | Spyres | NA |
| Hannah | St. Francis | NA |
| Andrew | Stolbach | Gamida Cell: Stock Shareholder, Phathom Pharmaceuticals: Stock Shareholder |
| Andrew | Stolbach | Gamida Cell: Stock Shareholder, Phathom Pharmaceuticals: Stock Shareholder |
| Mark | Su | NA |
| Jeffrey | Suchard | NA |
| Trevonne | Thompson | NA |
| Michael | Toce | NA |
| Joshua | Trebach | NA |
| Manoj | Tyagi | NA |
| Steven | Walsh | NA |
| Richard | Wang | NA |
| Christopher | Watson | NA |
| Paul | Wax | NA |
| Sage | Weiner | NA |
| James | Whitledge | NA |
| Timothy | Wiegand | NA |
| Brandon | Wills | NA |
| Stephen | Wood | NA |
| Alan | Woolf | NA |
| Brandtly | Yakey | NA |
| Luke | Yip | NA |
| Nasim | Zamani | NA |
| Matthew | Zuckerman | NA |

**Contact Information**

If you have questions regarding this enduring material activity, please contact Adrienne Dunavin at contact adrienne.dunavin@acmt.net.